[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626314":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":26,"responsibleParty":40,"collaborators":26,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":44,"sex":50,"minAge":51,"maxAge":26,"enrollmentInfo":52,"targetDuration":26,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":64,"whyStopped":26,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":26},{"fullName":5,"class":6},"University Hospital, Montpellier","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental group (ESPB)","EXPERIMENTAL","A single injection will be performed at the erector spinae plane site, 20 ml of ropivacaine 0.2% then 8 mg of dexamethasone (2 ml) will be administered sequentially through the same needle using two separate syringes in order to prevent the risk of precipitation between the two solutions. The injection will be performed unilaterally or bilaterally as per the randomization stratification",[13],"Procedure: Erector Spinae Plane Block with local anesthetic",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group (placebo)","PLACEBO_COMPARATOR","A single injection of 22 ml isotonic saline solution will be performed at the same anatomical site as the experimental group. To maintain the double-blind design, the saline solution will be administered sequentially through the same needle using two separate syringes (20 mL + 2 mL). The injection will also be performed unilaterally or bilaterally, according to the randomization stratification.",[19],"Procedure: Erector Spinae Plane Block with isotonic saline",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"PROCEDURE","Erector Spinae Plane Block with isotonic saline","Ultrasound-guided erector spinae plane block performed under aseptic conditions by an experienced physician, consisting of an interfascial injection in the erector spinae plane using an isotonic saline solution.",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Erector Spinae Plane Block with local anesthetic","Ultrasound-guided erector spinae plane block performed under aseptic conditions by an experienced physician, consisting of an interfascial injection in the erector spinae plane using a local anesthetic solution.",[9],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Sophie Bringuier, Pharm D PhD","CONTACT","+33467338661","s-bringuierbranchereau@chu-montpellier.fr",{"name":38,"role":34,"phone":26,"phoneExt":26,"email":39},"Xavier Cadevila, MD PHD","x-capdevila@chu-montpellier.fr",{"type":41,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100626314","erector-spinae-plane-block-for-acute-low-back-pain-100626314",false,"NCT07434024","Erector Spinae Plane Block for Acute Low Back Pain","Erector Spinae Plane Block for Acute Low Back Pain: a Prospective Double-blind Randomized Multicenter Study","ESP-BACK","Inclusion Criteria:\n\n* Adult (≥ 18 years);\n* Non-specific low back pain (≤ 5 days);\n* Pain score (VAS) ≥ 5 (during mobilization);\n* Inability to walk easily (failure of the \"Get Up and Go\" test in less than 20 seconds).\n\nExclusion Criteria:\n\n* Low back pain of known specific origin: spine surgery, spine trauma, discal hernia, facet joint, radicular (sciatica, cruralgia, meralgia paresthetica), muscle pain, cancer-related or rheumatological disease;\n* Referred or chronic pain;\n* Patients with opioids (acute or chronic pain and\u002For misuse);\n* Contraindication to regional anaesthesia;\n* Contraindication to ropivacaine, dexamethasone, sodium chloride, NSAID, paracetamol, tramadol;\n* Known hypersensitivity to ropivacaine, dexamethasone, other amide-type local anesthetics, or any of the excipients;\n* Addiction to drugs, alcohol or medication;\n* Patients with anticoagulants for a curative use (not preventive);\n* Patients with cancer or risk of bone metastasis or; severe osteoporosis;\n* Acute inflammatory diseases (e.g., rheumatoid arthritis, ankylosing spondylitis…);\n* Patient with severe hypotension or uncontrolled hypertension or; Heart Block (uncorrected second- or third-degree heart block without a pacemaker) or; severe bradycardia;\n* Patients with severe liver or renal disease or peptic ulcer disease;\n* Presence of infection or sepsis at the injection site;\n* Patients with uncontrolled bacterial, viral, or protozoan infections or; systemic fungal infections or; active untreated tuberculosis or; active ocular herpes simplex infections;\n* Patients with uncontrolled diabetes mellitus;\n* Patients with glaucoma or history of severe glaucoma;\n* Patients with severe psychiatric conditions;\n* Subject unable to read or\u002Fand write (inability to complete a self-administered questionnaire);\n* Unavailability for follow up during 6 months;\n* Participation in another clinical trial involving an investigational medicinal product or medical device within 4 weeks preceding the screening date;\n* Pregnancy in progress or planned during the study period or breastfeeding women (Art. L1121-5 of the French Public Health Code);\n* Women of childbearing potential (WOCBP) without a negative of highly sensitive pregnancy test before inclusion or not using a highly effective method of contraception;\n* Patients protected by law (Art. L1121-6 and L1121-8 of the French Public Health Code): Individuals deprived of their liberty by judicial or administrative decision, minors, adults under law protection or unable to express their consent or patient under guardianship or curatorship;\n* Patients not covered by a French social security scheme or not benefiting from such a scheme;\n* Absence of signed informed consent form before inclusion from the patient;\n* Patient already included in the study.","ALL","18 Years",{"count":53,"type":54},300,"ESTIMATED","INTERVENTIONAL",[57],"NA","Non-Specific low back pain (NSLB) is an important public health problem with a major economic and social impact. It is defined by the location of pain, between the lower rib margins and the lumbar vertebrae. Medical management of Non-Specific low back pain injury focuses on reducing pain and its consequences. Nowadays, no strategy has shown optimal effectiveness to improve outcome substantially. The ultrasound-guided erector spinae plane block (ESPB) is a well-known intermuscular compartment block. In the absence of red flag signs, ESPB can be performed for low back pain to reduce pain, decrease opiate requirements and limit emergency admissions for refractory pain. This study aims to evaluate the impact of the ESPB in patients suffering from NSLB.",[60],"Non-specific Low Back Pain (NSLBP)",[62,63],"Non-Specific low back pain ;","Erector Spinae Plane Block","NOT_YET_RECRUITING","2026-03-13",{"date":67,"type":68},"2026-03-17","ACTUAL",{"date":70,"type":54},"2026-03",{"date":72,"type":54},"2030-01",{"name":5,"class":6}]